FDA批准首款因子XIa抑制剂Sunharbo用于二级卒中预防
FDA approves first factor XIa inhibitor for secondary stroke prevention
FDA批准Sunharbo(asundexian)50mg片剂联合抗血小板疗法,用于降低近期轻至中度非心源性缺血性卒中或高危TIA成人患者的二级卒中风险。该药为首个获批的因子XIa抑制剂,基于OCEANIC-STROKE III期研究(12,327例患者),与安慰剂相比卒中风险降低26%。整体大出血率相近,但75岁以上患者及用药初期90天内出血风险升高,禁用于房颤患者卒中预防。
原文给出了首个因子XIa抑制剂获批的适应症、疗效数据及安全警示,可帮助读者了解该新机制药物的实际定位与使用限制。
The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).
Sunharbo is the first factor XIa inhibitor approved for use with antiplatelet therapy. However, concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers is not recommended due to a decrease in Sunharbo's effectiveness. Furthermore, Sunharbo is not recommended in patients with moderate or severe hepatic impairment, nor is it approved for stroke prevention in patients with atrial fibrillation.
The approval is based on results from the OCEANIC-STROKE phase 3 study, in which 12,327 adults with a noncardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk TIA were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset, in addition to antiplatelet therapy. Compared with placebo, Sunharbo 50 mg once daily significantly reduced the risk for ischemic stroke by 26% during a median treatment of 14.2 months.
The overall rate of major bleeding was similar between the groups, but was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Diarrhea was the most frequently reported adverse reaction (≥3% of Sunharbo-treated patients). Gastrointestinal bleeding occurred more often with Sunharbo than placebo.
"For those who survive a stroke, the risk of another potentially devastating event is highest in the days and weeks after the initial event, and that risk persists over time," Ashkan Shoamanesh, M.D., co-principal investigator of the OCEANIC-STROKE study at McMaster University, said in a statement. "I believe Sunharbo introduces an important new addition to poststroke care that can be used to help patients reduce the risk of a secondary stroke."
More information
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: FDA approves first factor XIa inhibitor for secondary stroke prevention (2026, November 17) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com